Huang Chiang-Ching, Fornage Myriam, Lloyd-Jones Donald M, Wei Gina S, Boerwinkle Eric, Liu Kiang
Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Circ Cardiovasc Genet. 2009 Aug;2(4):354-61. doi: 10.1161/CIRCGENETICS.108.828467. Epub 2009 Jun 10.
Mutations of PCSK9 are associated cross-sectionally with plasma low-density lipoprotein cholesterol (LDL-C) levels, but little is known about their longitudinal association with LDL-C levels from young adulthood to middle age.
We investigated the associations of 6 PCSK9 variants with LDL-C over 20 years in 1750 blacks and 1828 whites from the Coronary Artery Risk Development In Young Adults study. Generalized estimating equations were used to assess longitudinal differences in LDL-C levels between genotype categories. For blacks, LDL-C levels at age 18 were significantly lower (P<0.001) among those with 3 genetic variants (L253F, C679X, and Y142X; 81.5 mg/dL) and A443T (95.5 mg/dL) compared with noncarriers (109.6 mg/dL). The difference in LDL-C levels from noncarriers tended to widen for those with the 3 variants only, by 0.24 mg/dL per year of age (P=0.14). For whites with the R46L variant, compared with noncarriers, LDL-C levels at age 18 were significantly lower (84.4 mg/dL versus 100.9 mg/dL; P<0.001), and the increase in LDL-C with age was similar to noncarriers. The 3 genetic variants and the A443T variant in black men were associated with lower carotid intima-media thickness and lower prevalence of coronary calcification measured at ages 38 to 50.
Our results suggest that participants with several genetic variants of PCSK9 have persistently lower serum LDL-C levels than noncarriers from ages 18 to 50. Such long-term reduction in LDL-C levels is associated with reduced subclinical atherosclerosis burden in black men.
前蛋白转化酶枯草溶菌素9(PCSK9)的突变与血浆低密度脂蛋白胆固醇(LDL-C)水平呈横断面关联,但从青年期到中年期,其与LDL-C水平的纵向关联却知之甚少。
我们在“青年动脉粥样硬化风险发展研究”中,对1750名黑人及1828名白人的6种PCSK9变异体与LDL-C水平进行了20年的调查。采用广义估计方程评估不同基因型类别之间LDL-C水平的纵向差异。对于黑人,与非携带者(109.6mg/dL)相比,携带3种基因变异(L253F、C679X和Y142X;81.5mg/dL)和A443T变异(95.5mg/dL)的个体在18岁时的LDL-C水平显著更低(P<0.001)。仅携带3种变异体的个体与非携带者相比,LDL-C水平差异随年龄增长有扩大趋势,每年增加0.24mg/dL(P=0.14)。对于携带R46L变异体的白人,与非携带者相比,18岁时的LDL-C水平显著更低(84.4mg/dL对100.9mg/dL;P<0.001),且LDL-C随年龄的增加情况与非携带者相似。黑人男性中的3种基因变异体和A443T变异体与38至50岁时测量的较低颈动脉内膜中层厚度和较低冠状动脉钙化患病率相关。
我们的结果表明,携带多种PCSK9基因变异体的参与者在18至50岁期间的血清LDL-C水平持续低于非携带者。这种LDL-C水平的长期降低与黑人男性亚临床动脉粥样硬化负担减轻相关。